Fmr LLC acquired a new stake in shares of Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) in the 2nd quarter, reports. The institutional investor acquired 879,100 shares of the company’s stock, valued at approximately $3,648,000.

A number of research firms have weighed in on ARPO. Zacks Investment Research downgraded Aerpio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, June 25th. Needham & Company LLC began coverage on Aerpio Pharmaceuticals in a research report on Monday, July 23rd. They set a “buy” rating and a $10.00 price target on the stock. Guggenheim began coverage on Aerpio Pharmaceuticals in a report on Wednesday, September 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, HC Wainwright set a $9.00 price objective on Aerpio Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 15th.

ARPO opened at $2.60 on Friday. Aerpio Pharmaceuticals Inc has a 12 month low of $2.52 and a 12 month high of $6.25.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last released its quarterly earnings data on Tuesday, August 14th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The company had revenue of $1.33 million during the quarter. As a group, sell-side analysts anticipate that Aerpio Pharmaceuticals Inc will post -0.89 EPS for the current year.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Featured Article: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding ARPO? Visit to get the latest 13F filings and insider trades for Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO).

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with's FREE daily email newsletter.